Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Eli Lilly earnings topped Q4 views with 2025 guidance above consensus, even though Zepbound and Mounjaro slightly missed. Eli Lilly stock rose.

UnitedHealth Group, AbbVie, and Eli Lilly and Company are the three Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical stocks refer to equities in companies that are ...

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs by partnering with KeyBioscience in 2017. At one time, the Big Pharma was ...

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular ...

Eli Lilly has expanded a collaboration with ... against rivals such as Apple and FitBit whose wearable devices have an increasing medical focus with tech like ECG readers. ActiGraph provides ...

That’s how much Eli Lilly’s revenue grew in 2024, but it was still not as much as the company or investors expected, which had CEO David Ricks trying to assuage investors. Lilly on Tuesday ...

Eli Lilly stock rose after the drugmaker posted quarterly earnings that beat Wall Street expectations, and issued upbeat 2025 guidance. Fourth-quarter adjusted earnings came in at $5.32 a share, above ...

Eli Lilly shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected revenue.